


Carboplatin

Chemical Properties

CAS No. :	41575-94-4
Formula:	C ₆ H ₁₂ N ₂ O ₄ Pt
Molecular Weight:	371.25
Storage:	Keep away from direct sunlight Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Carboplatin (JM-8) is a cisplatin derivative, a DNA synthesis inhibitor. Carboplatin binds to DNA, inhibits replication and transcription, and induces cell death. Carboplatin has antitumor activity.
Targets(IC50)	Autophagy,DNA Alkylator/Crosslinker,DNA/RNA Synthesis
In vitro	<p>METHODS: 5637 cells were treated with Carboplatin (0-10000 μM) for 4 h. Cell viability was determined by MTT.</p> <p>RESULTS: Carboplatin showed a dose-dependent cell killing effect with an IC50 value of 289.3±2.90 μM. [1]</p> <p>METHODS: Human RB tumor cells Y79 were treated with Carboplatin (20-80 μg/mL) for 2 days, and apoptosis was detected by Flow Cytometry.</p> <p>RESULTS: Carboplatin induced an increase in the rate of early apoptosis. [2]</p>
In vivo	<p>METHODS: To test the antitumor activity in vivo, Carboplatin (20 mg/kg) was injected intravenously into the tail of BALB/c (nu/nu) mice harboring human RB tumor Y79 every three days for one or two weeks.</p> <p>RESULTS: Carboplatin successfully inhibited the growth of human RB xenografts in vivo. [2]</p> <p>METHODS: To detect anti-tumor activity in vivo, Carboplatin (25-75 mg/kg) was injected intraperitoneally into immunodeficient mice bearing EOC xenograft tumors once a week for six weeks.</p> <p>RESULTS: OV1946 and OV4453 were sensitive to Carboplatin, OV90 and OV4485 showed moderate response, and TOV21G and TOV112D were resistant. [3]</p>
Kinase Assay	Radioligand binding studies on human AT1 receptors: A radioligand binding assay is performed by using human AT1 receptor-coated microplates containing 4.4 to 6.2 fmol of receptors/well (10 μg of membrane protein/well). Membrane-coated wells are incubated with 45 μL of assay buffer (50 mM Tris-HCl, 5 mM MgCl ₂ , 1 mM EDTA, and 0.005% CHAPS, pH 7.4) containing various concentrations of Azilsartan at room temperature. After 90 minutes, 5 μL of 125I-Sar1-Ile8-All (final concentration 0.6 nM) dissolved in assay buffer is added to the wells, and the plate is incubated for 5 hours. In each step, the plate is briefly and gently shaken on a plate shaker. In washout experiments, the membranes are incubated with Azilsartan for 90 minutes, then immediately washed twice with 200 μL/well of assay buffer to remove unbound compounds, and further incubated for 5 hours with 125I-Sar1-Ile8-All. Membrane-

Kinase Assay	bound radioactivity is counted using a TopCount Microplate Scintillation and Luminescence Counter. In the experiments to estimate the dissociation rate of Azilsartan from AT1 receptors, membranes are incubated for 90 minutes with Azilsartan at a concentration of 30 nM for Azilsartan. Azilsartan inhibits the specific binding of 125I-Sar1-Ile8-AII to human AT1 by approximately 90%. The membranes are then immediately washed twice with 200 µL/well of assay buffer and further incubated with 125I-Sar1-Ile8-AII for 240 minutes. Membrane-bound radioactivity is counted using the TopCount Microplate Scintillation and Luminescence Counter at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes, 180 minutes, or 240 minutes. Nonspecific binding of 125I-Sar1-Ile8-AII is estimated in the presence of 10 µM unlabeled AII. Unlabeled AII is added again after washout for the washout experiment. Specific binding is defined as total binding minus nonspecific binding.
Cell Research	3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3-4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet. (Only for Reference)

Solubility Information

Solubility	DMF: 1 mg/mL (2.69 mM), Sonication is recommended. H2O: 12.5 mg/mL (33.67 mM), Sonication is recommended. (DMSO inactivates the activity of Carboplatin.) (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6936 mL	13.468 mL	26.936 mL
5 mM	0.5387 mL	2.6936 mL	5.3872 mL
10 mM	0.2694 mL	1.3468 mL	2.6936 mL
50 mM	0.0539 mL	0.2694 mL	0.5387 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wang S, et al. Analysis of the cytotoxic activity of carboplatin and gemcitabine combination. *Anticancer Res.* 2010 Nov;30(11):4573-8.

Liu L, Liu S, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. *Cancer Research.* 2021 Mar 1;81(5):1413-1425. doi: 10.1158/0008-5472.CAN-20-2125. Epub 2021 Jan 5.

Liu L, Liu S, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. *Cancer Research.* 2021, 81(5): 1413-1425.

Zhou Z, et al. Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo. *Int J Oncol.* 2020 Sep;57(3):697-706.

Brodeur MN, et al. Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. *Sci Rep.* 2021 Sep 14;11(1):18183.

Bi G, Liang J, Zhao M, et al. MiR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma by targeting CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. *Molecular Therapy-Nucleic Acids.* 2022

Wang H, et al. *Clin Cancer Res.* 2004, 10(5), 1633-1644.

Zhu H, Rao Z, Yuan S, et al. One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. *European Journal of Pharmacology.* 2021: 174366.

Guo A, Lin J, Zhong P, et al. Phellopterin attenuates ovarian cancer proliferation and chemoresistance by inhibiting the PU. 1/CLEC5A/PI3K-AKT feedback loop. *Toxicology and Applied Pharmacology.* 2023: 116691.

Liu H, et al. *Anticancer Res.* 2011, 31(9), 2713-2722.

Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. *Genome Med.* 2016 Oct 31;8(1):116.

Lin Y, Chen X, Lin L, et al. Sesamol serves as an MYH14 inhibitor to sensitize endometrial cancer to chemotherapy and endocrine therapy via suppressing MYH9/GSK3 β / β -catenin signaling. *Cellular & Molecular Biology Letters.* 2024, 29(1): 63.

Liu L, Liu S, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. *Cancer Research.*

Zhao X, Zhao Z, Li B, et al. ACSL4-mediated lipid rafts prevent membrane rupture and inhibit immunogenic cell death in melanoma. *Cell Death & Disease.* 2024, 15(9): 695.

Peng T, Ma X, Hua W, et al. Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy. *Cell Stem Cell.* 2025

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481